TSLP (Thymic Stromal Lymphopoietin): Complete Research Profile — TSLPR/CRLF2 Receptor Complex, JAK1-JAK2/STAT5 Signaling, Epithelial Alarmin Biology, and Laboratory Research Applications (2026)

Introduction: TSLP as the Upstream Alarmin of Type 2 Immunity

Thymic stromal lymphopoietin (TSLP) is a four-helix bundle cytokine that occupies a privileged position at the apex of the Type 2 immune cascade. Produced constitutively at low levels by epithelial cells at barrier surfaces — skin, airway, gut, and thymus — TSLP is dramatically upregulated when those barriers are damaged, infected, or exposed to allergens. The resulting cytokine burst activates dendritic cells, group 2 innate lymphoid cells (ILC2s), mast cells, and basophils, orchestrating the full spectrum of allergic and eosinophilic inflammation.

TSLP's clinical importance is underscored by tezepelumab (AMG 157/MEDI9929), an anti-TSLP monoclonal antibody approved by the FDA in 2021 for severe uncontrolled asthma. Its broad efficacy across eosinophilic, non-eosinophilic, and type 2-low asthma phenotypes — unlike narrower IL-5 or IL-4/IL-13-targeting biologics — reflects TSLP's upstream position in the inflammatory hierarchy. For researchers, recombinant TSLP and TSLP-pathway modulators are now essential tools for dissecting innate immune initiation, ILC2 biology, and epithelial-immune crosstalk.

This profile covers TSLP's molecular structure, isoforms, receptor signaling, cellular targets, research applications, and laboratory reagent considerations. All content is provided for research use only (RUO).

---

Molecular Biology of TSLP

Gene Structure and Protein

The human TSLP gene spans approximately 4 kb on chromosome 5q22.1 — within the type 2 cytokine gene cluster alongside IL-4, IL-5, and IL-13. The gene encodes a cytokine of the common gamma-chain (γc) family that shares structural homology with IL-7, consistent with its use of IL-7Rα as a shared receptor subunit.

Mature long-form TSLP (lfTSLP) contains 159 amino acids after signal peptide cleavage and folds into a four-helix bundle (helix A–D) topology characteristic of the type I cytokine superfamily. The protein is heavily glycosylated, contributing to a molecular weight of approximately 15–25 kDa depending on glycosylation state. A conserved disulfide bond stabilizes the AB loop, which is a critical contact site for TSLPR binding.

TSLP Isoforms: Long-Form vs. Short-Form

A critical but often overlooked aspect of TSLP biology is the existence of two distinct isoforms generated from alternative promoters:

Long-form TSLP (lfTSLP) uses a distal promoter and contains an additional 11-amino acid N-terminal extension. lfTSLP is the pro-inflammatory isoform responsible for driving allergic and eosinophilic inflammation. Transcription of lfTSLP is induced by NF-κB activation downstream of double-stranded RNA (viral mimetics), lipopolysaccharide (LPS), allergens, IL-4, IL-13, TNF-α, and barrier-disrupting proteases (e.g., Der p 1 cysteine protease from Dermatophagoides pteronyssinus).

Short-form TSLP (sfTSLP) is generated from a proximal promoter and encodes a 63-amino acid protein. sfTSLP is constitutively expressed at low homeostatic levels and appears to play a barrier maintenance and immune tolerance role rather than a pro-inflammatory one. Selective induction of sfTSLP versus lfTSLP has been proposed as a therapeutic strategy to preserve homeostasis without triggering pathological inflammation, though the precise functional differences between isoforms remain an active area of investigation.

---

TSLP Receptor Complex: TSLPR/CRLF2 and IL-7Rα

Receptor Architecture

TSLP signals through a heterodimeric receptor complex composed of:

1. TSLPR (TSLP Receptor) — encoded by CRLF2 (Cytokine Receptor-Like Factor 2) on chromosome Xp22.3/Yp11.3. TSLPR is a type I cytokine receptor with a single transmembrane domain and a short cytoplasmic tail that associates constitutively with JAK2.

2. IL-7Rα (CD127) — encoded by IL7R on chromosome 5p13. This receptor chain is shared with the IL-7 receptor and associates constitutively with JAK1.

TSLP binds initially to TSLPR with moderate affinity via Helix A and the AB loop. This binary complex then recruits IL-7Rα to form a high-affinity ternary signaling complex. The sequential binding mechanism has been validated by structural studies showing distinct contact footprints on IL-7Rα for TSLP versus IL-7, explaining why these cytokines signal differently despite sharing the receptor subunit.

JAK1/JAK2 Transphosphorylation and STAT5 Activation

Ternary complex formation juxtaposes JAK2 (TSLPR-associated) and JAK1 (IL-7Rα-associated), triggering transphosphorylation and kinase activation. Activated JAK1 and JAK2 phosphorylate tyrosine residues on the receptor cytoplasmic tails, creating docking sites for STAT5 SH2 domains. STAT5 is then phosphorylated at Tyr694 (STAT5A) or Tyr699 (STAT5B), dimerizes, and translocates to the nucleus.

In dendritic cells, TSLP-driven STAT5 activation induces transcription of OX40 ligand (OX40L), which programs naïve CD4+ T cells toward Th2 differentiation without IL-12 production — creating the "allergic dendritic cell" phenotype. In ILC2s, STAT5 drives expression of IL-5 and IL-13, fueling eosinophil recruitment and airway hyperresponsiveness.

TSLP also activates STAT3, MAPK/ERK, and PI3K/AKT pathways in a cell-type-dependent manner, contributing to proliferative and survival signaling beyond the canonical JAK-STAT5 axis.

Negative Regulation of TSLP Signaling

Receptor internalization following ligand binding provides negative feedback. SOCS proteins (particularly SOCS1 and SOCS3) are induced by TSLP itself and suppress JAK kinase activity. Protein tyrosine phosphatase receptor-type sigma (PTPRS/CD148) dephosphorylates JAK2 and attenuates TSLP signaling, providing cell-intrinsic brake mechanisms on prolonged activation.

---

Cellular Targets and Downstream Immune Activation

Dendritic Cells: The OX40L Bridge to Adaptive Immunity

TSLP-stimulated dendritic cells (DCs) upregulate OX40L while suppressing IL-12p70 production, biasing DC-T cell interactions toward Th2 polarization. TSLP-conditioned DCs induce naïve T cells to produce IL-4, IL-5, IL-13, and TNF-α, promoting pathogenic effector Th2 cell differentiation. This DC-mediated bridge explains why TSLP blockade can suppress adaptive allergic responses even when administered prior to allergen sensitization in preclinical models.

Group 2 Innate Lymphoid Cells (ILC2s)

ILC2s respond directly to TSLP through TSLPR and IL-7Rα co-expression. TSLP synergizes potently with IL-33 (acting through ST2) and IL-25 (acting through IL-17RB) to maximally activate ILC2s — the three epithelial alarmins forming a critical innate immune circuit. TSLP-activated ILC2s produce IL-5, IL-13, and amphiregulin, driving eosinophilia, mucus hypersecretion, and airway remodeling. In adipose tissue, ILC2 responses to TSLP are also linked to metabolic regulation and thermogenesis via IL-4 production.

Mast Cells and Basophils

TSLP promotes mast cell survival and augments IgE-mediated degranulation by upregulating FcεRI expression. In basophils, TSLP enhances IL-4 production and histamine release in response to IgE crosslinking, amplifying the immediate hypersensitivity response downstream of allergen exposure.

Eosinophils

While eosinophils express TSLPR at low levels, TSLP indirectly drives eosinophilia by stimulating IL-5 production from ILC2s and Th2 cells. Direct TSLP stimulation of eosinophils can modestly increase survival and IL-8 production, contributing to local tissue inflammation.

Regulatory T Cells and Immune Homeostasis

TSLP has complex, context-dependent effects on regulatory T cells. At homeostatic levels, sfTSLP-mediated IL-7Rα signaling may support peripheral Treg maintenance. However, under inflammatory conditions, TSLP-driven OX40L expression on DCs impairs Treg-mediated suppression, tipping the balance toward effector inflammation.

---

TSLP in Research Applications

Asthma and Chronic Airway Disease Research

TSLP was among the first cytokines identified as upregulated in bronchial biopsies of asthmatic patients. Preclinical models using intranasal TSLP administration induce eosinophilic inflammation, airway hyperresponsiveness, and remodeling in mice, establishing TSLP as a direct driver of asthma pathophysiology.

In human research contexts, TSLP mRNA and protein levels in bronchoalveolar lavage fluid correlate with asthma severity, eosinophil count, and degree of mucus plugging. TSLP drives both eosinophilic (Type 2-high) and neutrophilic (Th17-predominant) airway inflammation by conditioning DCs toward either Th2 or Th17 polarization depending on the inflammatory context — explaining the pan-asthma efficacy of tezepelumab versus narrower biologic targets. The Phase III NAVIGATOR trial demonstrated a 70% reduction in annualized asthma exacerbation rate with tezepelumab versus placebo regardless of baseline blood eosinophil count.

Atopic Dermatitis and Skin Barrier Research

In atopic dermatitis, filaggrin mutations and barrier disruption trigger TSLP release from keratinocytes. Lesional skin biopsies show markedly elevated TSLP mRNA compared to non-lesional tissue. TSLP-induced ILC2s and DCs drive Th2 skewing, Treg impairment, and itch via IL-31. K5-TSLP transgenic mouse models (keratin-5 promoter-driven skin-specific TSLP overexpression) display spontaneous skin lesions, elevated serum IgE, eosinophilia, and secondary airway inflammation, providing platforms for studying the skin-to-lung allergic march.

Eosinophilic Esophagitis Research

Esophageal epithelial cells from eosinophilic esophagitis (EoE) patients preferentially secrete high TSLP upon exposure to food antigens including egg ovalbumin, wheat, and milk proteins. TSLP secreted by terminally differentiated esophageal epithelium drives Th2 sensitization to food allergens penetrating a disrupted esophageal barrier. TSLP gene polymorphisms identified in genome-wide association studies of EoE and correlation of TSLP levels with histological disease severity position it as both a biomarker and research target in EoE models.

Tumor Microenvironment and CRLF2-Rearranged B-ALL Research

TSLP exerts context-dependent effects in tumor biology. Cancer-associated fibroblasts secrete TSLP that programs tolerogenic DCs in pancreatic ductal adenocarcinoma models, and TSLP from cervical cancer cells stimulates angiogenesis via VEGF.

In hematologic oncology, CRLF2 rearrangements — generating constitutively active TSLPR/JAK2 signaling — are driver mutations in a subset of B-cell acute lymphoblastic leukemia (B-ALL), particularly Down syndrome-associated ALL (DS-ALL). This subtype is characterized by high TSLPR/CRLF2 expression and co-occurring activating JAK2 mutations (e.g., JAK2 p.R683G), making the TSLP/CRLF2/JAK2 axis a validated oncogenic research target for novel therapeutic strategies including JAK inhibitors and anti-CRLF2 antibodies.

Gut Immunity and Food Allergy Research

Under homeostatic conditions, intestinal epithelial TSLP suppresses Th1/Th17 responses and maintains mucosal tolerance. Intestinal epithelium-specific TSLP knockout mice develop spontaneous Th1/Th17-driven colitis, establishing TSLP's role in gastrointestinal homeostasis. In sensitizing conditions, TSLP amplifies intestinal mast cell activation and ILC2-driven food allergy responses. TSLP-deficient mice show attenuated peanut allergy reactivity in preclinical sensitization models.

---

TSLP as a Research Reagent: Laboratory Applications

Recombinant TSLP Applications

Human recombinant TSLP (rhTSLP) is commercially available for in vitro RUO applications:

• •DC activation assays: rhTSLP (10–100 ng/mL, 24–48 hours) generates OX40L+ DCs from monocyte-derived precursors for downstream Th2 polarization studies.
• •ILC2 activation: rhTSLP (2–20 ng/mL) combined with IL-33 or IL-25 stimulates purified ILC2 preparations for Type 2 innate immune priming studies.
• •Basophil/mast cell pharmacology: Low-dose rhTSLP (1–10 ng/mL) enhances IgE-dependent mediator release for allergy pharmacology research.
• •Sensory neuron itch modeling: TSLP applied to dorsal root ganglion cultures activates TRPA1-expressing sensory neurons relevant to pruritus research in AD models.

Mouse recombinant TSLP requires species-matched reagents as cross-reactivity between human and mouse TSLP is poor.

TSLP Pathway Research Tools

Key Assay Considerations

STAT5 phosphorylation is transient — peak at 15–30 minutes post-stimulation — requiring rapid fixation for intracellular flow cytometry. OX40L induction on DCs peaks at 24–48 hours and is a highly sensitive and specific functional readout for TSLP bioactivity. When combining TSLP with IL-33 or IL-25 for ILC2 studies, concentration optimization is critical as synergistic effects can produce supra-additive responses at sub-EC50 concentrations.

---

TSLP in the Epithelial Alarmin Triad

TSLP functions as part of an alarmin triad alongside IL-33 and IL-25 (IL-17E). These three epithelial cytokines act in concert at barrier surfaces:

• •TSLP primarily programs DCs and directly activates ILC2s, mast cells, and basophils without requiring prior Th2 polarization.
• •IL-33 (ST2/IL-1RAcP signaling) synergizes with TSLP for maximal ILC2 activation and eosinophil survival.
• •IL-25 (IL-17RB signaling) amplifies ILC2 responses and Th2 differentiation.

TSLP and IL-33 form a positive feedback loop: TSLP upregulates ST2 expression on ILC2s, increasing IL-33 responsiveness, while IL-33 upregulates TSLPR on ILC2s, enhancing TSLP sensitivity. This mechanistic insight — that blocking TSLP alone may not fully suppress IL-33-driven ILC2 activation, and vice versa — is driving clinical development of bispecific antibodies simultaneously targeting TSLP and IL-33.

---

Important Research Disclaimer

All TSLP-related reagents described in this article are provided for Research Use Only (RUO) and are not approved for diagnostic or therapeutic use in humans or animals outside of regulated clinical trials. Tezepelumab (Tezspire) is FDA-approved for severe asthma under separate regulatory authorization. Researchers should adhere to all applicable institutional biosafety committee (IBC) and regulatory guidelines when working with recombinant cytokines. Personnel with known atopic or allergic conditions should exercise appropriate laboratory precautions when handling TSLP preparations.

---

Selected Research References

1. Cayrol C, Girard JP. Thymic stromal lymphopoietin (TSLP): an epithelial cytokine at the interface of innate and adaptive immunity. Immunity. 2022;55(5):777-794. doi:10.1016/j.immuni.2022.04.008

2. Corren J, et al. Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017;377(10):936-946. doi:10.1056/NEJMoa1704064

3. Menzella F, et al. Tezepelumab: patient selection and place in therapy in severe asthma. J Int Med Res. 2024. doi:10.1177/03000605241246740

4. Varricchi G, et al. Thymic Stromal Lymphopoietin (TSLP), Its Isoforms and the Interplay with the Epithelium in Allergy and Asthma. Int J Mol Sci. 2023;24(16):12725. doi:10.3390/ijms241612725

5. Ziegler SF. Role of thymic stromal lymphopoietin in allergy and beyond. Nat Rev Immunol. 2022. doi:10.1038/s41577-022-00735-y

6. Cianferoni A, et al. Preferential Secretion of TSLP by Terminally Differentiated Esophageal Epithelial Cells: Relevance to Eosinophilic Esophagitis. J Allergy Clin Immunol. 2016;137(4):1079-1089. doi:10.1016/j.jaci.2015.08.009

7. Russell LJ, et al. Deregulated CRLF2 expression in B-lineage acute lymphoblastic leukaemia. Blood Cancer J. 2017. doi:10.1038/bcj.2017.89

8. Frontiers in Pharmacology. Tezepelumab: redefining TSLP blockade in severe asthma through mechanistic precision and translational pharmacology. 2026. PMC13153638

9. Targeted deletion of the TSLP receptor reveals cellular mechanisms that promote type 2 airway inflammation. J Exp Med. 2020. PMC7311324

10. The Role of TSLP in Atopic Dermatitis: From Pathogenetic Molecule to Therapeutical Target. J Clin Med. 2023. PMC10122597